Nipah virus Glycoprotein G, His Tag (MALS verified)

ユーザーレビュー
製品番号/仕様
価格
数量
GLN-N52H3-50ug
$465.00
GLN-N52H3-500ug
$3170.00
ETA of in-stock products:2 business days
総アイテム数 製品金額$ 0

製品詳細

  • Synonyms

    Glycoprotein G (NiV)

  • Source

    Nipah virus Glycoprotein G, His Tag (GLN-N52H3) is expressed from human 293 cells (HEK293). It contains AA Gln 71 - Thr 602 (Accession # Q9IH62-1).

    Predicted N-terminus: His

    Request for sequence
  • Molecular Characterization

    Glycoprotein G (NiV) Structure

    Other Tags and Version Biotin & Other Labeled Version

    This protein carries a polyhistidine tag at the N-terminus.

    The protein has a calculated MW of 61.2 kDa. The protein migrates as 70-100 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Endotoxin

    Less than 1.0 EU per μg by the LAL method / rFC method.

  • Purity

    >85% as determined by SDS-PAGE.

    >95% as determined by SEC-MALS.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

お客様はこちらも閲覧

データ表示

  • SDS-PAGE

    Glycoprotein G (NiV) SDS-PAGE

    Nipah virus Glycoprotein G, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 85% (With Star Ribbon Pre-stained Protein Marker).

  • SEC-MALS

    Glycoprotein G (NiV) SEC-MALS

    The purity of Nipah virus Glycoprotein G, His Tag (Cat. No. GLN-N52H3) is more than 95% and the molecular weight of this protein is around 73-90 kDa verified by SEC-MALS.

    Report
  • Bioactivity-ELISA

     Glycoprotein G (NiV) ELISA

    Immobilized Nipah virus Glycoprotein G, His Tag (Cat. No. GLN-N52H3) at 5 μg/mL (100 μL/well) can bind Human Ephrin-B2 Protein, Fc tag (Cat. No. EPN-H5259) with a linear range of 0.1-2 ng/mL (QC tested).

    Protocol
  •  Glycoprotein G (NiV) ELISA

    Immobilized Nipah virus Glycoprotein G, His Tag (Cat. No. GLN-N52H3) at 1 μg/mL (100 μL/well) can bind Anti-Nipah/Hendra Glycoprotein G Antibody, Human IgG1 with a linear range of 0.03-1 ng/mL (Routinely tested).

    Protocol
  • Bioactivity-SPR

     Glycoprotein G (NiV) SPR

    Anti-Nipah/Hendra Glycoprotein G Antibody, Human IgG1 captured on Protein A Chip can bind Nipah virus Glycoprotein G, His Tag (Cat. No. GLN-N52H3) with an affinity constant of 0.188 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

    Protocol

ユーザーレビュー
コメントを投稿

バックグランド

Hendra virus (HeV) and Nipah virus (NiV) are henipaviruses discovered in the mid-to late 1990s that possess a broad host tropism and are known to cause severe and often fatal disease in both humans and animals. HeV and NiV infect host cells through the coordinated efforts of two envelope glycoproteins. The G glycoprotein attaches to cell receptors, triggering the fusion (F) glycoprotein to execute membrane fusion. G is a type II homotetrameric transmembrane protein responsible for binding to ephrinB2 or ephrinB3 (ephrinB2/B3) receptors. F is a homotrimeric type I transmembrane protein that is synthesized as a premature F0 precursor and cleaved by cathepsin L during endocytic recycling to yield the mature, disulfide-linked, F1 and F2 subunits. Upon binding to ephrinB2/B3, NiV G undergoes conformational changes leading to F triggering and insertion of the F hydrophobic fusion peptide into the target membrane. Subsequent refolding into the more stable post-fusion F conformation drives merger of the viral and host membranes to form a pore for genome delivery to the cell cytoplasm.

最新の進展

 
お問い合わせ
医薬品候補ライセンス
他の関連情報
  • 製品情報
  • 製品詳細
  • お客様はこちらも閲覧
  • データ表示
  • ユーザーレビュー
  • 背景
お問い合わせ

お問い合わせ
グローバル:+1 800-810-0816(Toll Free)

メールアドレス
order.jp@acrobiosystems.com

アクロバイオシステムズ株式会社
〒101-0051
東京都千代田区神田神保町1-32-8